Lenvima

Lenvatinib, the active ingredient in Lenvima, is a tyrosine kinase inhibitor presented as an oral tablet for systemic use. It is indicated for the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma in adult patients under medical supervision.

GNH USA supplies Lenvima as a licensed, Good Distribution Practice‑compliant international pharmaceutical provider, delivering the product to hospitals, oncology centres, pharmacies and clinics across global markets through reliable supply chains while adhering to regulatory standards and quality assurance protocols.

Lenvima (lenvatinib) is used in oncology to target multiple kinase‑driven tumor pathways.

- Differentiated thyroid cancer: improves progression‑free survival in patients with radioactive iodine‑refractory disease. - Renal cell carcinoma: combined with pembrolizumab to extend overall survival in advanced disease. - Hepatocellular carcinoma: employed as first‑line therapy for unresectable disease.

Lenvima may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Hypertension: elevated blood pressure requiring monitoring. - Diarrhea: loose stools that may lead to dehydration. - Nausea: feeling of sickness often accompanied by loss of appetite.

Serious or Rare Side Effects: - Hepatic failure: severe liver dysfunction requiring immediate medical attention. - Arterial thromboembolism: blood clots that can cause stroke or heart attack. - Severe hemorrhage: uncontrolled bleeding, especially gastrointestinal. - Gastrointestinal perforation or fistula formation. - Cardiac failure: reduced heart function presenting with shortness of breath.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor blood pressure: check regularly due to risk of hypertension. - Assess liver function: perform baseline and periodic tests. - Evaluate thyroid function: watch for hypothyroidism. - Avoid strong CYP3A4 inhibitors: may increase lenvatinib exposure. - Pregnancy: drug may cause fetal harm; avoid use in pregnant women. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Lenvima can interact with other medicines, necessitating careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may markedly increase lenvatinib exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Concomitant use with other VEGF inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Diuretics: may potentiate hypertension. - Antihypertensive agents: dose adjustments may be needed.